retatrutide weight loss clinical trials FDA Approval Status 2026: Everything We Know So Far BEYOND OZEMPIC: ELI LILLY RETATRUTIDE

Where it works: Liver: Increases hepatic glucose production and fat oxidation (when carbs are low) Adipose tissue: Stimulates lipolysis (breakdown of stored fat into free fatty acids) Brown adipose tissue: Activates thermogenesis (heat production from burning fat) Muscle: May increase fat oxidation during exercise Weight loss contribution: The glucagon component appears to add an additional 2-3% weight loss beyond the GLP-1/GIP combination (24% vs 22% for tirzepatide)

These medications seem to be very effective at cutting out the time it takes to lose weight, and that can have potentially life-saving benefits

17, 2024, has been updated to reflect new information

Ongoing research will continue to clarify how they compare

What can be said is that the triple-agonist mechanism appears to produce a steeper dose-response curve than either the dual-agonist (tirzepatide) or single-agonist (semaglutide) approach

In Embla's peer-reviewed study, we proved that if you do the intensive behavior health and lifestyle coaching correctly, you only need about 1/3 the typical dose of GLP1, to get 16.7% average weight loss